Early experience with linezolid for infections in orthopaedics

Injury

Volumn 37, Issue 9, 2006, Pages 818-826

  Harwood, P J ^a   Talbot, C ^b   Dimoutsos, M ^c   Sunderland, G ^d   Shaw, D ^b   Wilcox, M H ^e   Giannoudis, P V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

^c EVANGELISMOS HOSPITAL   (Greece)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Complications; Infection; Linezolid; MRSA; Orthopaedic; Resistant; Trauma

Indexed keywords

LINEZOLID; METAL; PENICILLIN G; RIFAMPICIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE CLASSIFICATION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; FEMALE; HEALTH SURVEY; HOSPITAL DISCHARGE; HUMAN; IMPLANT; INFECTION RESISTANCE; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL PARAMETERS; MOUTH ULCER; NAUSEA; ORGAN; ORTHOPEDIC EQUIPMENT; ORTHOPEDIC SURGERY; OSTEOMYELITIS; PRIORITY JOURNAL; SEPSIS; SKIN MANIFESTATION; STAPHYLOCOCCUS INFECTION; STATISTICAL ANALYSIS; SURGICAL INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VOMITING;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; RECURRENCE; REOPERATION; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 33747149935     PISSN: 00201383     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.injury.2006.02.007     Document Type: Article

References (38)

1. http://www.hpa.org.uk/cdr/PDFfiles/2004/cdr2904.pdf
2. Anonymous. MRSA with intermediate resistance to teicoplanin. Commun Dis Report Weekly 10 (2000) 99-102
3. Aucken H.M., Warner M., Ganner M., et al. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 46 (2000) 639-640
4. Birmingham M.C., Rayner C.R., Meagher A.K., et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 2 (2003) 159-168
5. Bouza E., and Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 7 Suppl 4 (2001) 75-82
6. Bozdogan B., and Appelbaum P.C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23 2 (2004) 113-119
7. Broder K.W., Moise P.A., Schultz R.O., et al. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and post-operative osteomyelitis. Ann Plast Surg 52 4 (2004) 385-390
8. Burnie J., Matthews R., Jiman-Fatami A., et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 31 (2000) 684-689
9. Charles P.G.B., Ward P.B., Johnson P.D., et al. Clinical fearures associated with bacteraemia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
10. Dailey C.F., Pagano P.J., Buchanan L.V., et al. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47 (2003) 2655-2658
11. Diekema D.J., BootsMiller B.J., Vaughn T.E., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 1 (2004) 78-85
12. Grohs P., Kitzis M.D., and Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 47 1 (2003) 418-420
13. Guerin F., Buu-Hoi A., Mainardi J.L., et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 38 (2000) 2985-2988
14. Harwood P.J., and Giannoudis P.V. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic resistant organisms. Expert Opin Drug Saf 3 5 (2004) 405-414
15. Henwood C.J., Livermore D.M., Johnson A.P., et al. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 46 6 (2000) 931-940
16. Howe R.A., and Walsh T.R. hGISA: seek and ye shall find. Lancet 364 (2004) 500-501
17. Kofron M.D., Opsitnick N.C., Attawia M.A., and Laurencin C.T. Cryopreservation of tissue engineered constructs for bone. J Orthop Res 21 6 (2003) 1005-1010
18. Kutscha-Lissberg F., Hebler U., Muhr G., and Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 47 12 (2003) 3964-3966
19. Lipsky B.A., Itani K., and Norden C. Treating foot infections in diabetic patients: a randomised, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 38 1 (2004) 17-24
20. Lovering A.M., Zhang J., Bannister G.C., et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 50 1 (2002) 73-77
21. MacGowan A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51 Suppl 2 (2003) ii17-ii25
22. Marchese A., Schito G.C., and Debbia E.A. Evolution of antibiotic resistance in gram-positive pathogens. J Chemother 12 6 (2000) 459-462
23. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin Infect Dis 39 (2004) 1010-1015
24. Miller K., O'Neill A.J., Wilcox M.H., et al. Suppression of linezolid resistance in Staphylococcus aureus using drug combinations. Proceedings of the 44th interscience conference on antimicrobial agents and chemotherapy, Americal society for microbiology. Washington, DC (2004)
25. Moise P.A., Forrest A., Birmingham M.C., and Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to vancomycin. J Antimicrob Chemother 50 6 (2002) 1017-1026
26. Nathwani D., Barlow G.D., Ajdukiewicz K., et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother 51 2 (2003) 391-396
27. NINSS. Surveillance of surgical site infection in English hospitals 1997-2001 (2002), PHLS
28. Nishi J.I., Shirao K., Ito H., et al. Difference in incidence and transmission mode of methicillin-resistant Staphylococcus aureus among surgery, orthopedics, and pediatrics wards: a prospective study at a university hospital. Infect Control Hosp Epidemiol 19 2 (1998) 107-109
29. Pallares R., Dick R., Wenzel R.P., et al. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 14 (1993) 376-382
30. Rana B., Butcher I., Grigoris P., et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 50 5 (2002) 747-750
31. Rao N., Ziran B.H., Hall R.A., and Santa E.R. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 427 (2004) 67-71
32. Reacher M.H., Shah A., Livemore D.M., et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Brit Med J 320 (2000) 213-216
33. Sanderson P.J. The role of methicillin-resistant Staphylococcus aureus in orthopaedic implant surgery. J Chemother 13SpecNo1 1 (2001) 89-95
34. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340 (1999) 493-501
35. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 11 (2002) 1481-1490
36. Tam V.H., Jumbe N.L., Briceland L.L., and Miller M.H. A comparative study of vancomycin and lactams in the treatment of staphylococcal bacteraemia in hemodialysis patients. Proceedings of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA (1995)
37. Wilcox M.H. Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother 51 Suppl 2 (2003) ii27-ii35
38. Wilson S.E. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and post-operative gram-positive infections. Surg Infect (Larchmt) 2 1 (2001) 25-35